CONCLUSION-Dyspepsia is a frequently occurring complaint in primary care and patients are usually treated by their GP. Besides clinically relevant reasons for referral, dyspeptic patients with irritable bowel syndrome seem to be more “at risk” of being referred to secondary care than other dyspeptic patients. The differences between primary and secondary care dyspeptic patients should be taken into account when interpreting research for guideline purposes. Further research is needed to clarify the background of the relation between irritable bowel syndrome and dyspepsia and its influence on referral.
In 2006, a large Japanese multi-centre clinical trial using mosapride in the treatment of functional dyspepsia was published. Mosapride demonstrated effectiveness, substantially reducing the feelings of abdominal discomfort and fullness.
72% cases had daily intake of tea or coffee (more than 2 cups per day) and 68% cases had sedentary life style, whereas 50% cases had spicy and oily food and 46% had non-vegetarian diet. 32% cases had alcohol consumption and smoking/tobacco chewing, respectively.
Inclusion Criteria. Newly diagnosed cases of uncomplicated gastroesophageal reflux disease with hiatus hernia patients (aged between 20 and 60 years) with symptoms of gastroesophageal reflux disease whose diagnosis has been confirmed by endoscopy and manometry.
Follow up was done and any adverse drug reactions were noted and finally at the end of two weeks outcome was assessed. Levosulpiride is a prescription medicine for conditions like GERD, IBS, Indigestion, Depression, and Dyspepsia. It belongs to the class of medications called atypical antipsychotic drugs.
For some patients, tegaserod was highly effective in the treatment of slow-transit constipation. Without tegaserod, unmanageable constipation would require surgical removal of the colon for some patients. Approximately 60% of patients have minimal side effects and can tolerate this drug. Others have to discontinue this medication due to bothersome side effects such as fatigue or a feeling of agitation, and in rare cases, as already mentioned, abnormal muscle movements, or what is called tardive dyskinesia.
Appropriate dose adjustments should be made based on the response of the patients. This medicine should be used with caution in patients having low potassium levels in the body. It is recommended to initiate treatment with Levosulpiride only after the potassium deficit is corrected.
Do not start, stop, or change the dosage of any medicines without your doctor’s approval. Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and persistent cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus.
But if they show up and continue for a long period, inform your doctor to get medical attention and treated properly. Your doctor may suggest a change in medication based on the condition. into the oesophagus.
Among patients with HCV genotype 3 infection, 96% in the ribavirin-free group achieved an SVR12 (27/28; 95% CI, 82 – 99; 1 relapse), and 100% in the ribavirin group achieved an SVR12 (27/27; 95% CI, 88 – 100). The most common adverse events were headache, fatigue, and nausea.
Cisapride soon became a first-line medical treatment option for patients with upper motility disorders. observed that itopride is effective in the treatment of functional dyspepsia as it was well tolerated and had only few adverse drug reactions in the form of diarrhoea, dizziness, increased salivation and facial flushing. Thus, individual drug dose selection is advisable. Nausea was observed more in itopride group during and after treatment than levosulpiride group. Nausea was seen in 50.70% cases before treatment and in 18.14% cases after treatment with levosulpiride and with itopride it was 35% before and 71.40% after treatment.
It is doubtful it will come to the North American market due to reports of carcinogenic problems, which have shown up in the obligatory chronic (long-term) studies conducted in animals. These animal studies are part of the data that must be prepared for regulatory pre-market submissions.